Tempest Therapeutics files to allow resale of up to 9.5M shares by selling stockholders; company gets no proceeds

Filed October 2, 2026 · ~1 min read

Key Changes

• high

  The prospectus covers resale of up to 9,534,164 shares by selling stockholders, consisting of shares issuable upon exercise of pre-funded, Series C, Series D, and placement agent warrants.

  The Offering verify on EDGAR →
• high

  Tempest is not selling any shares and will not receive proceeds from these resales; it may receive cash if warrants are exercised.

  The Offering verify on EDGAR →
• medium

  The shares are broken into 3,105,591 pre-funded warrants, 3,105,591 Series C warrants, 3,105,591 Series D warrants, and 217,391 placement agent warrants.

  The Offering verify on EDGAR →